Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.

Trial Details

NCT ID
NCT05340491
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Toripalimab
  • Chemotherapy
  • Intensity modulated radiotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Beijing, China|39.9075,116.39723
  • Chengdu, China|30.66667,104.06667
  • Fuzhou, China|26.06139,119.30611
  • Guiyang, China|26.58333,106.71667

Key Eligibility Criteria

  • Diagnosed as local with or without regional recurrence after ≥1 year of radical treatment;
  • Not suitable for surgery;
  • Histologic diagnosis of NPC (WHO II/III);
  • TNM stage rII-IVa (AJCC/UICC 8th);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →